New FDA Approval: Deucravacitinib (Sotyktu), a First-In-Class Oral, Allosteric Tyrosine Kinase 2 Inhibitor

In September 2022, deucravacitinib (Sotyktu), a first-in-class oral, allosteric tyrosine kinase 2 (TYK2) inhibitor for moderate-to-severe plaque psoriasis, was approved by the FDA. Aside from its first-in-class mechanism of action, it is the first approved de novo deuterated drug.

This premium deep dive into deucravacitinib includes:

  • the industry context
  • the clinical data
  • the target rationale
  • the mechanism of action
  • the drug’s origins
deucravacitinib (Sotyktu), deuterated TYK2 inhibitor, Newly approved for patients with plaque psoriasis, Deuteromethylamide suppresses N-demethylation via deuterium kinetic isotope effect, High selectivity for TYK2 over JAK1, JAK2, and JAK3

See our overview of all 36 of the novel small molecule and large molecule FDA approvals for 2022 here.

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in:

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.

This field is for validation purposes and should be left unchanged.